MTNB News and Press, Matinas Biopharma Holdings Inc. From 05/02/24

BEDMINSTER, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that it will report fi...

BEDMINSTER, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that MAT2203, its or...

A look at the top 10 most actives in the United States Kintara Therapeutics Inc. (KTRA) rose 63.3% to $0.164 on volume of 223,092,889 shares C3is Inc. (CISS) rose 24.2% to $0.0508 on volume of 148,576,579 shares Nikola Corporation (NKLA) fell 8.4% to $0.8918 on volume of 128,870,418 share...

A look at the top 10 most actives in the United States Kintara Therapeutics Inc. (KTRA) rose 99.9% to $0.2007 on volume of 121,318,217 shares Next.e.GO N.V. (EGOX) rose 30.8% to $0.034 on volume of 63,981,361 shares C3is Inc. (CISS) rose 20.8% to $0.0494 on volume of 63,446,681 shares I...

2024-04-03 08:38:32 ET More on Matinas Biopharma Seeking Alpha’s Quant Rating on Matinas Biopharma Historical earnings data for Matinas Biopharma Financial information for Matinas Biopharma Read the full article on Seeking Alpha For further det...

BEDMINSTER, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE American: MTNB) (“Matinas BioPharma” or the “Company”), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrysta...

2024-03-28 23:20:23 ET Matinas BioPharma Holdings, Inc. (MTNB) Q4 2023 Earnings Conference Call March 27, 2024 04:30 PM ET Company Participants Jody Cain - LHA Investor Relations Jerome Jabbour - Chief Executive Officer Theresa Matkovits - Chief Development Offic...

2024-03-27 16:46:08 ET More on Matinas Biopharma Seeking Alpha’s Quant Rating on Matinas Biopharma Historical earnings data for Matinas Biopharma Financial information for Matinas Biopharma Read the full article on Seeking Alpha For further det...

Clear registration pathway and FDA agreement on the ORALTO Phase 3 trial for MAT2203 represent critical steps forward and supports partnership discussions Continued success of Compassionate/Expanded Use Access Program demonstrates potential of MAT2203 in treating multiple severe invasiv...

Daily oral LNC-docetaxel, at a total administered dose of more than 8x greater than IV-docetaxel, showed no evidence of weight loss, compared to an average peak weight loss of 20% with IV-docetaxel Results build on data from prior in vivo study of oral LNC-docetaxel showing reductio...